Dossier assessment
Voclosporin (lupus nephritis) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Voclosporin (lupus nephritis) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Voclosporin (lupus nephritis) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Adults with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis
Result of dossier assessment:
Added benefit not proven
Project details
- Project no.
- A23-16
- Commission
- Commission awarded on 27.02.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Kidneys and urinary system
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.